The Utility of PET Brain Imaging in the Initial Evaluation of Dementia

Journal of the American Medical Directors Association

Volumn 8, Issue 3, 2007, Pages 150-157

  Weaver, Jonathan D ^a   Espinoza, Randall ^b   Weintraub, Nancy T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

assessment; Dementia; health services; neuroimaging

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CONGO RED; DIMETHYLAMINODICYANONAPHTHALENEPROPENE F18; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; THIOFLAVINE; TRACER; UNCLASSIFIED DRUG;

ALGORITHM; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MEDICARE; MEMORY DISORDER; MENTAL DISEASE; MULTIINFARCT DEMENTIA; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REIMBURSEMENT; REVIEW; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HEALTH CARE COSTS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UNITED STATES;

EID: 33847413588     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.10.004     Document Type: Review

References (72)

1. Copeland J.R.M., Davidson I.A., Dewey M.E., et al. Alzheimer's disease, other dementias, depression, and pseudodementia: Prevalence, incidence, and three-year outcome in Liverpool. Br J Psychiatry 161 (1992) 230-239
2. Stevens T., Livingston G., Kitchen G., Manela M., Walker Z., and Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry 180 (2002) 270-276
3. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: Study methods and prevalence of dementia. Can Med Assoc J 150 (1994) 899-912
4. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: Prevalence estimates using the 2000 Census. Arch Neurol 60 (2003) 1119-1122
5. Evans D.A. Estimated prevalence of Alzheimer disease in the United States. Milbank Q 68 (1990) 267-289
6. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88 (1998) 1337-1342
7. Cummings J.L. Drug therapy: Alzheimer's Disease. N Engl J Med 351 (2004) 56-67
8. Weiner M.F., Martin-Cook K., Foster B.M., Saine K., Fontaine C.S., and Svetlik D.A. Effects of donepezil on emotional/behavioral symptoms in AD patients. J Clin Psychiatry 61 (2000) 487-492
9. Burns A., Rosser M., Hecker J., et al., Donepezil Study Group. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 10 (1999) 237-244
10. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291 (2004) 317-324
11. Hill J.W., Futterman R., Duttagupta S., Mastey V., Lloyd J.R., and Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 58 (2002) 62-70
12. Gutterman E.M., Markowitz J.S., Lewis B., and Fillit H. Cost of Alzheimer's disease and related dementia in managed-Medicare. J Am Geriatr Soc 47 (1999) 1065-1071
13. The net cost of Alzheimer's disease and related dementia: A population-based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord 14 (2000) 151-159
14. National Institute on Aging. 2003 Progress Report on Alzheimer's Disease. Available at: www.nia.nih.gov/NR/rdonlyres/0C3612EF-3C01-44EA-899B-223909A6DEEE/0/2003_Progress_Report_on_AD.pdf+ALZHEIMERS+DISEASE+COSTS&access=p&output=xml_no_dtd&ie=UTF-8&client=NIA_frontend&site=NIA&oe=UTF-8. Accessed August 1, 2006.
15. Donepezil Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 51 (2003) 737-744
16. Hill J.W., Futterman R., Mastey V., and Fillit H. The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface 15 (2002) 63-70
17. Leon J., Cheng C.K., and Neumann P.J. Alzheimer's disease care: Costs and potential savings. Health Aff (Millwood) 17 (1998) 206-216
18. Ross G.W., Abbott R.D., Petrovich H., et al. Frequency and characteristics of silent dementia among elderly Japanese-American men: The Honolulu-Asia Aging Study. JAMA 277 (1997) 800-805
19. Ryan D.H. Misdiagnosis in dementia: Comparisons of diagnostic error rate and range of hospital investigation according to medical specialty. Int J Geriatr Psychiatry 9 (1994) 141-147
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
21. Holmes C., Cairns N., Lantos P., et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 174 (1999) 45-50
22. Jobst K.A., Barnetson L.P., and Shepstone B.J. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and apo E4 in medial temporal lobe dementias. Oxford project to investigate memory and aging. Int Psychogeriatr 10 (1998) 271-302
23. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1143-1153
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (1994), American Psychiatric Association, Washington, DC
25. Yesavage J.A., Brink T.L., Rose T.L., et al. Development and validation of a geriatric depression screening scale. J Psychiatr Res 17 (1982) 37-49
26. Clarfield A.M. The reversible dementias: Do they reverse?. Ann Intern Med 109 6 (1988) 476-486
27. Clarfield A.M. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 163 18 (2003) 2219-2229
28. Chui H., and Shang Q. Evaluation of dementia: A systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 49 (1997) 925-935
29. Victoroff J., Mack W.J., Lyness S.A., et al. Multicenter clinicopathological correlation in dementia. Am J Psychiatry 152 (1995) 1476-1484
30. Nagy Z., Hindley N.J., Braak H., et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by "stages": A prospective study. Dement Geriatr Cogn Disord 10 (1999) 109-114
31. Bonte F.J., Weiner M.F., Bigio E.H., et al. Brain flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 202 (1997) 793-797
32. Mielke R., and Heiss W.D. Positron emission tomography for diagnosis of AD and vascular dementia. J Neural Transm 53 (1998) 237-250
33. Herholz K., Schopphoff H., Schmidt M., et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 43 (2002) 21-26
34. Frackowiak R.S., Magistretti P.J., Shulman R.G., Altman J.S., and Adams M. Neuroenergetics: Relevance for functional brain imaging (2001), Human Frontier Science Program, Srasbourg
35. Mielke R., Kessler J., Szelies B., Herholz K., Wienhard K., and Heiss W.D. Normal and pathological aging-findings of positron-emission-tomography. J Neural Transm 105 8-9 (1998) 821-837
36. Foster N.L., Chase T.N., Fedio P., Patronas N.J., Brooks R.A., and DiChiro G. Alzheimer's disease: Focal cortical changes shown by positron emission tomography. Neurology 33 (1983) 961-965
37. Mielke R., Pietrzyk U., Jacobs A., et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: Comparison of perfusion and metabolic pattern. Eur J Nucl Med 21 (1994) 1052-1060
38. Devous Sr. M.D. Functional brain imaging in the dementias: Role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med Mol Imaging 29 (2002) 1685-1696
39. Zakzanis K., Graham S.J., and Campbell Z. A meta-analysis of structural and functional brain imaging in dementia of Alzheimer's type: A neuroimaging profile. Neuropsychol Rev 13 (2003) 1-18
40. Herholz K., Salmon E., Perani D., et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17 (2002) 302-316
41. Silverman D.H.S., Small G.W., and Phelps M.E. Clinical value of neuroimaging in the diagnosis of dementia: Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of AD. Clin Positron Imaging 2 (1999) 119-130
42. 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45 (2004) 594-607
43. Geerlings M.I., Jonker C., Bouter L.M., Ader H.J., and Schmand B. Association between memory complaints and incident Alzheimer disease in elderly people with normal baseline cognition. Am J Psychiatry 156 (1999) 531-537
44. Petersen R.C., Smith G.E., Waring S.C., et al. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9 suppl 1 (1997) 65-69
45. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56 (1999) 303-308
46. Ganguli M., Dodge H.H., Shen C., and DeKosky S.T. Mild cognitive impairment, amnestic type: An epidemiologic study. Neurology 63 1 (2004) 115-121
47. Arnaiz E., Jelic V., Almkvist O., et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12 4 (2001) 851-855
48. Silverman D.H.S., Truong C., Kim S.K., et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: Comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 80 3 (2003) 350-355
49. Silverman D.H.S., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia. Regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
50. Peterson R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
51. Heidebrink J.L. Is dementia with Lewy bodies the second most common cause of dementia?. J Geriatr Psychiatr Neurol 15 (2002) 182-187
52. McKeith I.G., Dickson D.W., Lowe J., et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65 12 (2005) 1863-1872
53. Gilman S., Koeppe R.A., Little R., et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with FDG and neuropsychological testing. Exp Neurol 191 (2005) S95-S103
54. Bowler J.V. Vascular cognitive impairment. J Neurol Neurosurg Psychiatry 76 Suppl 5 (2005) v35-v44
55. Grimmer T., Diehl J., Drzezga A., Forstl H., and Kurz A. Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: A prospective 18F-FDG-PET study. Dement Geriatr Cogn Disord 18 (2004) 32-36
56. Karbe H., Grond M., Huber M., Herholz K., Kessler J., and Heiss W.D. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol 239 (1992) 98-102
57. Soong B., Liu R., Wu L., Lu Y., and Lee H. Metabolic characterization of spinocerebellar ataxia type 6. Arch Neurol 58 (2001) 300-304
58. Volkow N.D., Hitzemann R., Wang G.J., et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 11 (1992) 184-190
59. O'Brien J. Dementia associated with psychiatric disorders. Int Psychogeriatr 17 Suppl 1 (2005) S207-S221
60. Mental Health. A Report of the Surgeon General: Executive Summary (1999), Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, Rockville, MD. http://www.surgeongeneral.gov/library/mentalhealth/home.html Available at: www.surgeongeneral.gov/library/mentalhealth/home.html
61. Gallo J.J., Rabins P.V., and Anthony J.C. Sadness in older persons: 13-year follow-up of a community sample in Baltimore, Maryland. Psychol Med 29 2 (1999) 341-350
62. Mayberg H.S., Liotti M., Brannan S.K., McGinnis S., Mahurin R.K., Jerabek P.S., et al. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am J Psychiatry 156 5 (1999) 675-682
63. Kumar A., Newberg A., Alavi A., Berlin J., Smith R., and Reivich M. Regional cerebral glucose metabolism in late life depression and Alzheimer disease: A preliminary positron emission tomography study. Proc Natl Acad Sci U S A 90 15 (1993) 7019-7023
64. Parsey R.V., and Mann J.J. Applications of positron emission tomography in psychiatry. Semin Nucl Med 33 2 (2003) 129-135
65. Silverman D.H.S., Gambhir S.S., Huang H.W.C., et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. J Nuc Med 43 (2002) 253-266
66. 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neur 12 (2005) 254-264
67. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 303-305
68. Agdeppa E.D., Kepe V., Liu J., et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 21 24 (2001) RC189
69. Ito K., Nagano-Saito A., Kato T., et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: A 6-[(18)F]fluoro-L-dopa PET study. Brain 125 (2002) 1358-1365
70. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with lewy bodies. Neurology 55 10 (2000) 1575-1577
71. Shinotoh H., Namba H., Fukushi K., et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study. Ann Neurol 48 (2000) 194-200
72. Herholz K., Bauer B., Wienhard K., et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: Comparison with blood flow and glucose metabolism. J Neural Transm 12 (2000) 1457-1468